Methodology

All entries for: Immune Diseases

June 23, 2026

Tourmaline Bio

Layoffs

New York, NY
1-50 employees

Tourmaline Bio said goodbye to 60 employees at its New York headquarters months after being swallowed by Novartis.

The workforce reduction stems from the closure of a Tourmaline site at 27 West 24th in New York, according to a Workers Adjustment and Retraining Notification (WARN) alert for the state. The layoffs took effect May 29, though the notice was only posted last week.

Novartis moved to acquire Tourmaline in September last year, putting around $1.4 billion on the line on a fully diluted basis, the pharma said at the time. The transaction closed in late October.

Novartis has conducted several rounds of layoffs this year, including one that takes effect in August and will leave 76 New Jersey workers jobless. The pharma also announced in May that it would shutter a Germany facility by the end of 2028, which will affect 220 jobs. Novartis ran two other cycles of terminations—one in March and another in April—which together affected more than 170 staff in New Jersey.

Disease Area: Cardiology, Immune Diseases, Multiple
Drug Type: Biologic
Source
Source
June 12, 2026

Genentech

Layoffs

South San Francisco, CA
10,000+ employees

Genentech has made changes to its research and early development group (gRED) that include parting ways with a high-profile executive who had been with the company since 1997. The South San Franciso–based biotech confirmed to BioSpace the “targeted adjustments” and departure of Vishva Dixit, who most recently served as vice president and senior fellow, physiological chemistry, research biology.

The restructuring is intended to ensure the Roche subsidiary’s capabilities and investments align with its core therapeutic areas, advance its portfolio and deliver transformative medicines to patients faster, according to Genentech. A spokesperson declined to share specific information about the layoffs, including how many employees were affected.

Endpoints News reported that Genentech is closing infectious disease and physiological chemistry units while downsizing other teams. Also, in addition to Dixit, other key departures include Todd McDevitt, vice president and head of cell therapy, and Man-Wah Tan, a vice president and senior fellow of infectious diseases, the media outlet reported.

Disease Area: Dermatology, Immune Diseases, Infectious Diseases, Multiple, Oncology, Rare Diseases, Respiratory Diseases
Drug Type: Biologic, Small Molecule
Source
Source
May 27, 2026

Johnson & Johnson

Layoffs

New Brunswick, NJ
10,000+ employees

New Jersey’s job market is taking another hit, this time from pharma giant Johnson & Johnson, which is parting ways with 56 employees in New Brunswick, according to a Worker Adjustment and Retraining Notification (WARN) Act posting for the state. The layoffs will take effect on August 21.

This is J&J’s first announced workforce reduction of this year, according to a tally by BioSpace. But the pharma has for years been constantly reshaping its business to accommodate the loss of exclusivity of its autoimmune disease powerhouse Stelara—a campaign that has involved cutting back investments in other parts of its business, while putting more money into higher-value areas like cancer.

Other Big Pharma players to recently slash their New Jersey headcounts include Novartis, Bristol Myers Squibb and Novo Nordisk.

Disease Area: Immune Diseases, Multiple, Neurological Diseases, Oncology
Drug Type: Biologic, Small Molecule
Source
Source
May 22, 2026

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

Novartis is continuing to trim its workforce in the U.S., letting go of 76 employees in East Hanover, New Jersey, according to a Worker Adjustment and Retraining Notification (WARN) Act alert for the state. The layoffs will take effect on Aug. 21.

This will be the third time this year that Novartis downsized its New Jersey operations. The first batch of layoffs was announced in March, affecting 114 employees set to take effect from June 26 through Nov. 27. The second hit came a month later, with 60 jobs projected to be cut from July 24 through Nov. 20.

Novartis earlier this month also announced that it would close down a production site in Germany by the end of 2028, eliminating 220 jobs in the process.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple
Drug Type: Biologic, Small Molecule
Source
Source
May 15, 2026

Novartis

Layoffs

Basel, Baselstadt
10,000+ employees

Novartis is letting go of “a select number” of employees within its biomedical research organization, a company spokesperson confirmed to BioSpace in an emailed statement.

“Novartis continually assesses opportunities to support our growth strategy as a focused innovative medicines company,” the statement read. “We regularly evaluate our organizational setup to ensure it remains aligned with evolving priorities.”

The cuts are the latest in a series of made or projected layoffs at Novartis this year that in total affect nearly 400 employees. Earlier this month, the Swiss pharma announced plans to shutter a production facility in Wehr, Germany, by the end of 2028. Novartis expects that closure will eliminate 220 jobs. In March and April, the pharma disclosed between two Worker Adjustment and Retraining Notification (WARN) Act notices that it will let go of 174 employees in East Hanover, New Jersey. Of those cuts, layoffs affecting 114 people are effective June 26 through Nov. 27, while those impacting 60 staffers run from July 24 through Nov. 20.

Disease Area: Cardiovascular, Dermatology, Immune Diseases, Multiple, Oncology
Drug Type: Biologic, Small Molecule
Source
Source
May 15, 2026

Takeda

Layoffs

Tokyo
10,000+ employees

To cut back on costs, Takeda is rolling out a sweeping “transformation program” that will streamline corporate operations and see some 4,500 employees let go in fiscal year 2026, according to an earnings presentation. That number represents less than 10% of total roles globally and does not reflect hiring plans, a company spokesperson told BioSpace in an emailed response on May 13.

“Right now, we have 2,200 open roles globally and we expect to create new jobs throughout the year, which we are prioritizing filling with internal candidates,” the spokesperson said.

The layoffs will look different across the organization and will be phased according to unique business needs and country requirements, according to the spokesperson. They confirmed that the cuts include an estimated 247 roles in Massachusetts and 387 in other states outlined in a March Worker Adjustment and Retraining Notification (WARN) Act notice.

Disease Area: Dermatology, Immune Diseases, Multiple, Neurological Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
Source
Source
May 14, 2026

First Tracks Biotherapeutics, Inc.

Neutral Outlook

San Diego, CA
51-200 employees

Thus, it is unclear how the IRA will be implemented but it will likely have a significant impact on the pharmaceutical industry and the pricing of our products and product candidates.

Disease Area: Chronic Disease, Immune Diseases
Drug Type: Biologic
Source
Source
May 14, 2026

Candel Therapeutics, Inc.

Neutral Outlook

Needham, Massachusetts
51-200 employees

While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain that it will not affect our patent strategy in the long run.

Disease Area: Immune Diseases, Oncology
Drug Type: Biologic
Source
Source
May 13, 2026

Adicet Bio, Inc.

Neutral Outlook

Boston, MA
51-200 employees

The effects of the IRA on our business and the healthcare industry in general is not yet known.

Disease Area: Hematology, Immune Diseases, Oncology
Drug Type: Biologic
Source
Source
May 12, 2026

CalciMedica, Inc.

Neutral Outlook

La Jolla, California
1-50 employees

While we do not believe that the IRA or its effects will impact our ability to obtain patents in the near future, we cannot be certain whether it will affect our patent strategy in the long run.

Disease Area: Cardiology, Gastrointestinal, Immune Diseases, Respiratory Diseases
Drug Type: Small Molecule
Source
Source
Scroll to Top